Back to results
US 2017/0290852 A1Published application
Micelle formulations of amphotericin b
AssigneeWisconsin Alumni Research Foundation
InventorGlen S. KWON
Life of this patent
Estimating the term…
Abstract
The present technology relates generally to micelle formulations of amphotericin B that optionally include 5-fluorocytosine and methods of preparing such formulations. Methods of treating fungal infections with the present compositions are also provided.
Claims26
A composition comprising:
- pegylated-phospholipid,
- amphotericin B,
- a water-soluble deoxycholate salt, and
- saline,
- wherein:
- the mole ratio of amphotericin B to pegylated-phospholipid is about 1:25 to about 1:200, and
- the concentration of pegylated-phospholipid is above its critical micelle concentration.
4 more elements
A composition comprising:
- a pegylated-phospholipid selected from PEG-DSPE, wherein the PEG block has an average molecular weight of about 3000 Da to about 7000 Da;
- about 0.05-0.2 mg/mL amphotericin B;
- about 0.05-0.2 mg/mL deoxycholate sodium salt;
- and
- saline having a concentration of 0.5 wt % to 1.5 wt % sodium chloride;
- wherein
- the mole ratio of amphotericin B to PEG-DSPE is about 1:30 to 1:100, and
- the concentration of PEG-DSPE is above its critical micelle concentration.
5 more elements
Dependencies are inferred from the claim text.